Associated Papers
Oral Melanocytic Neoplasms: A Narrative Review.
Maldonado-Mendoza J
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025
Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy.
Pakkianathan J et al.
Journal of Clinical Medicine, 2025
ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders.
Sande CM et al.
The Journal of Clinical Investigation, 2025
On the Boundary of Exploratory Genomics and Translation in Sequential Glioblastoma.
Tompa M et al.
International Journal of Molecular Sciences, 2024
Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria.
Lee Y et al.
Cancers, 2024
RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma.
Song X et al.
The Journal of Clinical Investigation, 2024
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
Zeng PYF et al.
Cell Reports, 2024
The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation.
Gorria T et al.
Cancers, 2024
New molecular prognostic factors of adult diffuse lower-grade gliomas in post-2016 molecular era: a retrospective analysis from single center.
Wang Q et al.
British Journal of Neurosurgery, 2023
Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue.
Kim SC et al.
Scientific Data, 2023
DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
Singh J et al.
Journal of Neuro-oncology, 2023
Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review.
Serman N et al.
Bosnian Journal of Basic Medical Sciences, 2022
Detection of TERT Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances.
Hasanau T et al.
Biomedicines, 2022
Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK et al.
Acta Neuropathologica, 2022
Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error.
Lee H et al.
Cancer Research and Treatment, 2022
American Association of Neuropathologists, Inc. Abstracts of the 97th Annual Meeting June 10-13, 2021 St. Louis, Missouri.
Unknown Author
Journal of Neuropathology and Experimental Neurology, 2021
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
Singh A et al.
Cells, 2021
Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.
Soares P et al.
Endocrine Pathology, 2021
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Sievers P et al.
Acta Neuropathologica, 2020
Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
Menezes WP et al.
Cells, 2020
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.
Rheinbay E et al.
Nature, 2020
Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.
Krings G et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2018
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Pozdeyev N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2018
Reconstructing the molecular life history of gliomas.
Barthel FP et al.
Acta Neuropathologica, 2018
Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.
Jeong DE et al.
Oncology Letters, 2017
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Scott SN et al.
Cancer Cytopathology, 2017
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
de Graaff MA et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2016
TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U et al.
Journal of Neuro-oncology, 2016
Biomarker-based prognostic stratification of young adult glioblastoma.
Zhang RQ et al.
Oncotarget, 2016
TERT promoter mutations are rare in bone and soft tissue sarcomas of Japanese patients.
Saito T et al.
Molecular and Clinical Oncology, 2016
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG et al.
Journal of the National Cancer Institute, 2014
Clonal architectures and driver mutations in metastatic melanomas.
Ding L et al.
Plos One, 2014
Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B status.
Tosefsky K et al.
Neuro-oncology Advances, 0